Immunovant Inc (IMVT)

Sector:
FINANCE
Industry:
GENERAL FINANCE
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Pete Salzmann
Employees:
320 WEST 37TH STREET, NEW YORK, NY 10018
917-580-3099

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. The company is based in New York, New York.

Data derived from most recent annual or quarterly report
Market Cap 473.012 Million Shares Outstanding116.505 Million Avg 30-day Volume 359.467 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.15
Price to Revenue0.0 Debt to Equity0.0 EBITDA-156.688 Million
Price to Book Value1.2863 Operating Margin0.0 Enterprise Value110.516 Million
Current Ratio11.521 EPS Growth0 Quick Ratio11.367
1 Yr BETA 1.3657 52-week High/Low 11.38 / 3.15 Profit Margin0.0
Operating Cash Flow Growth0.0 Altman Z-Score7.0491 Free Cash Flow to Firm 0
Earnings Report2022-08-09
View SEC Filings from IMVT instead.

View recent insider trading info

Funds Holding IMVT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IMVT BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-30:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-07:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-05:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-30:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-23:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2021-11-17:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-27:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    2 Thousand total shares from 2 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BUTCHKO JULIA G. CHIEF DEV. & TECH. OFFICER

    • Officer
    282,074 2022-05-24 6

    SALZMANN PETER CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    555,635 2022-05-24 6

    MACIAS WILLIAM L. CHIEF MEDICAL OFFICER

    • Officer
    195,948 2022-04-19 4

    LEVINE MARK S. CHIEF LEGAL OFFICER

    • Officer
    526,000 2022-01-28 2

    MIGAUSKY GEORGE V

    • Director
    220,718 2022-01-10 2

    FROMKIN ANDREW J.

    • Director
    276,399 2022-01-10 2

    PANDE ATUL

    • Director
    275,899 2022-01-10 2

    TORTI FRANK

    • Director
    702,474 2022-01-10 1

    HUGHES DOUGLAS J.

    • Director
    289,146 2022-01-10 2

    BARNETT EVA RENEE CHIEF FINANCIAL OFFICER

    • Officer
    172,541 2022-01-07 4

    ROIVANT SCIENCES LTD.

    • 10% Owner
    73,388,664 2021-08-02 1

    JAIN RITA CHIEF MEDICAL OFFICER

    • Officer
    471,665 2021-03-19 0

    YANCHIK CONNEALY PAMELA CHIEF FINANCIAL OFFICER

    • Officer
    208,200 2021-03-19 0

    ELLIOTT MICHAEL JAMES CHIEF SCIENTIFIC OFFICER

    • Officer
    439,900 2021-03-19 0

    WONG RODERICK CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    902,498 2019-12-11 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SALZMANN PETER - Director - Officer CHIEF EXECUTIVE OFFICER

    2022-05-25 16:23:29 -0400 2022-05-24 S 1,471 $3.79 d 555,635 direct 4.9751 12.6866 12.6866 6 0.0 1

    BUTCHKO JULIA G. - Officer CHIEF DEV. & TECH. OFFICER

    2022-05-25 16:26:04 -0400 2022-05-24 S 492 $3.79 d 282,074 direct 4.9751 12.6866 12.6866 6 0.0 1

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    IMMUNOVANT INC IMVT 2022-06-30 22:15:03 UTC 1.2095 0.3605 1200000
    IMMUNOVANT INC IMVT 2022-06-30 21:45:03 UTC 1.2095 0.3605 1200000
    IMMUNOVANT INC IMVT 2022-06-30 21:15:03 UTC 1.2095 0.3605 1200000
    IMMUNOVANT INC IMVT 2022-06-30 20:45:03 UTC 1.2095 0.3605 1200000
    IMMUNOVANT INC IMVT 2022-06-30 20:15:04 UTC 1.2095 0.3605 1200000
    IMMUNOVANT INC IMVT 2022-06-30 19:45:03 UTC 1.2095 0.3605 1200000
    IMMUNOVANT INC IMVT 2022-06-30 19:15:03 UTC 1.2095 0.3605 1200000
    IMMUNOVANT INC IMVT 2022-06-30 18:45:04 UTC 1.2095 0.3605 1200000
    IMMUNOVANT INC IMVT 2022-06-30 18:15:04 UTC 1.2095 0.3605 1200000
    IMMUNOVANT INC IMVT 2022-06-30 17:45:03 UTC 1.2095 0.3605 1200000
    IMMUNOVANT INC IMVT 2022-06-30 17:15:03 UTC 1.2095 0.3605 1200000
    IMMUNOVANT INC IMVT 2022-06-30 16:45:04 UTC 1.1887 0.3813 1200000
    IMMUNOVANT INC IMVT 2022-06-30 16:15:03 UTC 1.1887 0.3813 1200000
    IMMUNOVANT INC IMVT 2022-06-30 15:45:03 UTC 1.1887 0.3813 1200000
    IMMUNOVANT INC IMVT 2022-06-30 15:15:03 UTC 1.1887 0.3813 1200000
    IMMUNOVANT INC IMVT 2022-06-30 14:45:03 UTC 1.1887 0.3813 1200000
    IMMUNOVANT INC IMVT 2022-06-30 14:15:03 UTC 1.1887 0.3813 1200000
    IMMUNOVANT INC IMVT 2022-06-30 13:45:03 UTC 1.1873 0.3827 1100000
    IMMUNOVANT INC IMVT 2022-06-30 13:15:03 UTC 1.1873 0.3827 1100000
    IMMUNOVANT INC IMVT 2022-06-30 12:45:03 UTC 1.1873 0.3827 1100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments